Breast Cancer, Breast Tumor, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Metastatic Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer
Conditions
Keywords
Breast Cancer, Cancer of the Breast, Metastatic Breast Cancer, Metastatic Triple Negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Metastatic Breast Cancer, Basal-like breast cancer, Hormone receptor negative breast cancer, Estrogen receptor negative breast cancer, Progesterone negative receptor breast cancer, HER2 Negative Breast Cancer, Abraxane, nab-Paclitaxel, ABI-007, gemcitabine, Gemzar, carboplatin, Paraplatin, Paraplatin AQ, Phase 2, Phase 3
Brief summary
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.
Detailed description
ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer. Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.
Interventions
DRUGnab-Paclitaxel
nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
DRUGCarboplatin
Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
DRUGGemcitabine
Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Sponsors
Celgene
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
A subject will be eligible for inclusion in this study only if all of the following criteria are met: 1. Female subjects, age ≥ 18 years at the time informed consent is signed 2. Pathologically confirmed adenocarcinoma of the breast 3. Pathologically confirmed as triple negative, source documented, defined as both of the following 1. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: \< 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls) 2. Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i. Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH) negative (or equivalent negative test). Subjects with IHC 2 must have a negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test). 4. Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2 positive) must have pathologic confirmation of triple negative disease in at least one of the current sites of metastasis 5. Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease. a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician. 6. Subjects with measurable metastatic disease, defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) guidelines 7. Life expectancy ≥ 16 weeks from randomization 8. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to Grade 1 or less. 9. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required. a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization 10. Prior radiotherapy must have completed before randomization, with full recovery from acute radiation side effects. At least one measurable lesion must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal, in accordance with RECIST 1.1 guidelines 11. At least 30 days from major surgery before randomization, with full recovery 12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 13. Subject has the following blood counts at screening: * Absolute Neutrophil Count (ANC) ≥ 1500/mm\^2 ; * Platelets ≥ 100,000/mm\^2 ; * Hemoglobin (Hgb) ≥ 9 g/dL 14. Subject has the following blood chemistry levels at screening: * Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT), Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤ 2.5 x upper limit of normal range (ULN); if hepatic metastases present ≤ 5.0 x ULN * Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin within normal range in subjects with documented Gilbert's Syndrome * Creatinine clearance \> 60 mL/min (by Cockcroft-Gault) 15. Females of child-bearing potential \[defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)\] must: * Demonstrate a negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL; and * Either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, two physician approved effective contraception methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption for 28 days or longer as required by local guidelines, prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of the study or longer as required by local guidelines 16. Females must abstain from breastfeeding starting at randomization, during study participation and for 28 days or longer as required by local guidelines, after IP discontinuation 17. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted 18. Able to adhere to the study visit schedule and other protocol requirements
Exclusion criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply: 1. Male subjects 2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior immunotherapy & monoclonal antibody therapy are acceptable. 3. Subjects who received prior cytotoxic chemotherapy after incomplete resection of locoregional recurrent disease 4. History of, or known current evidence of brain metastasis, including leptomeningeal involvement. 5. Subjects with bone as the only site of metastatic disease 6. Subjects with regional lymph node as the only site of metastatic disease 7. Serious intercurrent medical or psychiatric illness, including serious active infection 8. History of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization 9. History of other primary malignancy in the last 5 years prior to randomization. Subjects with prior breast cancer history are eligible, however, the most recently obtained biopsy must demonstrate triple negative disease (source documented). Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible. 10. Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable allergies which, in the opinion of the investigator, may lead to serious complications 11. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 12. Subjects who have received an investigational product within the previous 4 weeks prior to randomization 13. Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study 14. Pregnant or nursing women 15. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents 16. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study 17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study 18. Any condition that confounds the ability to interpret data from the study 19. History of seropositive human immunodeficiency virus (HIV) 20. Subjects who are receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. | From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C | PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy | Cycle 6 | The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications. |
| Kaplan-Meier Estimates of Overall Survival | From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C | Overall survival was defined as the time from the date of randomization to the date of death (from any cause). |
| Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment. | Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C | Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir. |
| Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C | The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. |
| Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs | From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C | Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose. |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C | Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death. |
Countries
Australia, Austria, Brazil, Canada, France, Germany, Greece, Italy, Portugal, Spain, United Kingdom, United States
Participant flow
Recruitment details
This multicenter study was conducted by investigators in 11 countries in North America, Europe, Australia and South America, and enrolled participants at a total of 86 sites. Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.
Pre-assignment details
Participants were randomized 1:1:1, stratified by disease free interval (≤ 1 year; \> 1 year).
Participants by arm
| Arm | Count |
|---|---|
| Arm A: Nab-Paclitaxel Plus (+) Gemcitabine Participants received nab-Paclitaxel 125 mg/m\^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m\^2 on Days 1 and 8 by IV administration in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. | 61 |
| Arm B: Nab-Paclitaxel + Carboplatin Participants received nab-Paclitaxel 125 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. | 64 |
| Arm C: Gemcitabine + Carboplatin Participants received gemcitabine 1000 mg/m\^2 on Days 1 and 8 by IV administration, followed by carboplatin AUC 2 on Days 1 and 8 by IV administration in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. | 66 |
| Total | 191 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 9 | 13 | 12 |
| Overall Study | Death | 2 | 0 | 1 |
| Overall Study | Given Commercially Available Drug | 0 | 0 | 2 |
| Overall Study | Miscellaneous | 3 | 3 | 0 |
| Overall Study | Non-Compliance with Study Drug | 1 | 2 | 0 |
| Overall Study | Physician Decision | 4 | 3 | 6 |
| Overall Study | Progressive Disease | 31 | 35 | 36 |
| Overall Study | Protocol Violation | 1 | 1 | 0 |
| Overall Study | Symptomatic Deterioration | 3 | 3 | 1 |
| Overall Study | Untreated: Death | 0 | 0 | 1 |
| Overall Study | Untreated: Other | 0 | 0 | 1 |
| Overall Study | Untreated: Withdrawal Before Study Start | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 6 | 4 | 6 |
Baseline characteristics
| Characteristic | Total | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|---|
| Age, Continuous | 54.9 years STANDARD_DEVIATION 11.67 | 53.7 years STANDARD_DEVIATION 12.16 | 54.3 years STANDARD_DEVIATION 11.96 | 56.7 years STANDARD_DEVIATION 10.87 |
| Current Sites of Metastasis Abdomen/Peritoneal | 6 participants | 1 participants | 2 participants | 3 participants |
| Current Sites of Metastasis Bone | 69 participants | 23 participants | 21 participants | 25 participants |
| Current Sites of Metastasis Liver | 56 participants | 17 participants | 16 participants | 23 participants |
| Current Sites of Metastasis Lung/Thoracic | 125 participants | 42 participants | 42 participants | 41 participants |
| Current Sites of Metastasis Lymph Nodes(s) | 139 participants | 38 participants | 50 participants | 51 participants |
| Current Sites of Metastasis Other | 31 participants | 13 participants | 10 participants | 8 participants |
| Current Sites of Metastasis Right/Left Breast | 51 participants | 15 participants | 19 participants | 17 participants |
| Current Sites of Metastasis Skin/Soft Tissue | 34 participants | 13 participants | 13 participants | 8 participants |
| Disease Free Interval by Clinical Interpretation ≤ 1 year | 53 Years | 17 Years | 16 Years | 20 Years |
| Disease Free Interval by Clinical Interpretation > 1 year | 136 Years | 43 Years | 48 Years | 45 Years |
| Disease Free Interval by Clinical Interpretation Missing | 2 Years | 1 Years | 0 Years | 1 Years |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 = Fully Active | 114 Participants | 34 Participants | 38 Participants | 42 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 = Restrictive but ambulatory | 73 Participants | 25 Participants | 26 Participants | 22 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 2 = Ambulatory but unable to work | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Missing | 3 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race Black or African American | 23 Participants | 9 Participants | 6 Participants | 8 Participants |
| Race Unknown or Not Reported | 9 Participants | 2 Participants | 3 Participants | 4 Participants |
| Race White | 159 Participants | 50 Participants | 55 Participants | 54 Participants |
| Sex: Female, Male Female | 191 Participants | 61 Participants | 64 Participants | 66 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Stage of Primary Diagnosis Stage 0 | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Stage of Primary Diagnosis Stage IA | 24 Participants | 7 Participants | 6 Participants | 11 Participants |
| Stage of Primary Diagnosis Stage IB | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Stage of Primary Diagnosis Stage IIA | 38 Participants | 14 Participants | 9 Participants | 15 Participants |
| Stage of Primary Diagnosis Stage IIB | 24 Participants | 8 Participants | 7 Participants | 9 Participants |
| Stage of Primary Diagnosis Stage IIIA | 22 Participants | 9 Participants | 10 Participants | 3 Participants |
| Stage of Primary Diagnosis Stage IIIB | 11 Participants | 3 Participants | 3 Participants | 5 Participants |
| Stage of Primary Diagnosis Stage IIIC | 8 Participants | 3 Participants | 3 Participants | 2 Participants |
| Stage of Primary Diagnosis Stage IV | 38 Participants | 11 Participants | 17 Participants | 10 Participants |
| Time from Diagnosis to First Documented Disease/Relapse | 40.0 months STANDARD_DEVIATION 51.46 | 38.8 months STANDARD_DEVIATION 49.46 | 29.9 months STANDARD_DEVIATION 37.18 | 50.9 months STANDARD_DEVIATION 62.6 |
| Time from First Documented Metastatic Disease/Relapse to Study Randomization | 2.6 months STANDARD_DEVIATION 11.07 | 2.1 months STANDARD_DEVIATION 5.08 | 4.2 months STANDARD_DEVIATION 18.39 | 1.6 months STANDARD_DEVIATION 1.7 |
| Time from Primary Diagnosis to Randomization | 44.0 months STANDARD_DEVIATION 53.53 | 43.7 months STANDARD_DEVIATION 54.6 | 35.5 months STANDARD_DEVIATION 40.51 | 52.5 months STANDARD_DEVIATION 62.37 |
| Triple-Negative at Latest Diagnosis | 187 Participants | 60 Participants | 62 Participants | 65 Participants |
| Triple-Negative Breast Cancer (TNBC) at Primary Diagnosis | 152 Participants | 51 Participants | 53 Participants | 48 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 59 / 60 | 63 / 64 | 62 / 64 |
| serious Total, serious adverse events | 22 / 60 | 20 / 64 | 25 / 64 |
Outcome results
Primary
Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.
PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.
Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Population: ITT includes all randomized participants regardless of whether they received any IP or had any efficacy assessments collected. Those who did not have disease progression or had not died as of the data cutoff date were censored at the time of the last radiologic assessment prior to the data cutoff date.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. | 5.5 months |
| Arm B: Nab-Paclitaxel + Carboplatin | Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. | 8.3 months |
| Arm C: Gemcitabine + Carboplatin | Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. | 6.0 months |
Comparison: For stratified analysis, the stratified log-rank test and stratified Cox proportional hazards model were used, where the stratification factor is the disease free interval (\<= 1 year; \> 1 year).p-value: 0.018395% CI: [1.089, 2.629]Log Rank
Comparison: For stratified analysis, the stratified log-rank test and stratified Cox proportional hazards model were used, where the stratification factor is the disease free interval (\<= 1 year; \> 1 year).p-value: 0.015295% CI: [0.373, 0.904]Log Rank
Comparison: For stratified analysis, the stratified log-rank test and stratified Cox proportional hazards model were used, where the stratification factor is the disease free interval (\<= 1 year; \> 1 year).p-value: 0.859995% CI: [0.676, 1.597]Log Rank
Secondary
Kaplan-Meier Estimates of Overall Survival
Overall survival was defined as the time from the date of randomization to the date of death (from any cause).
Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Population: The ITT population includes all randomized participants regardless of whether the participant received any Investigational Product (IP) or had any efficacy assessments collected.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Kaplan-Meier Estimates of Overall Survival | 12.1 months |
| Arm B: Nab-Paclitaxel + Carboplatin | Kaplan-Meier Estimates of Overall Survival | 16.8 months |
| Arm C: Gemcitabine + Carboplatin | Kaplan-Meier Estimates of Overall Survival | 12.6 months |
Comparison: Hazard ratios and associated two-sided 95% confidence intervals were estimated using stratified Cox proportional hazard model. The stratification factor is the disease free interval (≤ 1 year; \> 1 year).p-value: 0.157995% CI: [0.882, 2.143]Log Rank
Comparison: Hazard ratios and associated two-sided 95% confidence intervals were estimated using stratified Cox proportional hazard model. The stratification factor is the disease free interval (≤ 1 year; \> 1 year).p-value: 0.294595% CI: [0.52, 1.221]Log Rank
Comparison: Hazard ratios and associated two-sided 95% confidence intervals were estimated using stratified Cox proportional hazard model. The stratification factor is the disease free interval (≤ 1 year; \> 1 year).p-value: 0.669195% CI: [0.71, 1.708]Log Rank
Secondary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.
Time frame: From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Population: The safety population includes all randomized participants who received at least 1 dose of IP.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of Gemcitabine | 13 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of nab-Paclitaxel | 31 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment Related TEAE leading to death | 1 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Any TEAE | 60 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of Carboplatin | 0 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Any Grade 3 or Higher TEAE | 46 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of Carboplatin | 0 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of nab-Paclitaxel | 27 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related TEAE | 59 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of Carboplatin | 0 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related, Grade 3 or Higher TEAE | 35 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of Carboplatin | 0 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Serious TEAE | 22 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of Gemcitabine | 18 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related Serious TEAE | 10 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of Gemcitabine | 31 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of Gemcitabine | 7 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of Carboplatin | 0 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Dose Reduction (DR) of IP | 23 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment Related (TR) TEAE Leading to D/C of IP | 12 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Death | 2 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of nab-Paclitaxel | 21 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment related TEAE Leading to DR of IP | 23 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of Gemcitabine | 18 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Dose Interruption (DI) of IP | 31 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of Gemcitabine | 24 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of nab-Paclitaxel | 22 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE Leading to DI of IP | 27 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Discontinuation (D/C) of IP | 16 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of nab-Paclitaxel | 16 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of Carboplatin | 0 participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of nab-Paclitaxel | 11 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of Gemcitabine | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of nab-Paclitaxel | 13 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of nab-Paclitaxel | 19 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of nab-Paclitaxel | 19 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of nab-Paclitaxel | 50 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of Gemcitabine | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of Gemcitabine | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment related TEAE Leading to DR of IP | 20 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of Gemcitabine | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of Carboplatin | 28 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of Carboplatin | 25 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of Carboplatin | 50 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of Carboplatin | 17 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Death | 1 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of Carboplatin | 17 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment Related TEAE leading to death | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of nab-Paclitaxel | 44 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of Carboplatin | 44 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of Gemcitabine | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Any TEAE | 63 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Any Grade 3 or Higher TEAE | 51 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE Leading to DI of IP | 44 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related TEAE | 62 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related, Grade 3 or Higher TEAE | 43 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Serious TEAE | 20 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related Serious TEAE | 9 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Discontinuation (D/C) of IP | 29 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment Related (TR) TEAE Leading to D/C of IP | 27 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Dose Reduction (DR) of IP | 20 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Dose Interruption (DI) of IP | 50 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of Gemcitabine | 0 participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of nab-Paclitaxel | 17 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE Leading to DI of IP | 44 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related TEAE | 60 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related, Grade 3 or Higher TEAE | 46 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Serious TEAE | 25 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment Related (TR) TEAE Leading to D/C of IP | 12 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Dose Reduction (DR) of IP | 25 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of nab-Paclitaxel | 0 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of nab-Paclitaxel | 0 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of nab-Paclitaxel | 0 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of Gemcitabine | 13 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of Gemcitabine | 9 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of Gemcitabine | 25 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of Gemcitabine | 23 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of Gemcitabine | 43 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to D/C of Carboplatin | 12 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of Carboplatin | 20 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of Carboplatin | 43 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Any Grade 3 or Higher TEAE | 54 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment-related Serious TEAE | 13 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Discontinuation (D/C) of IP | 15 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment related TEAE Leading to DR of IP | 23 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Dose Interruption (DI) of IP | 50 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Any TEAE | 64 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of nab-Paclitaxel | 0 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DR of nab-Paclitaxel | 0 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TR TEAE leading to DI of nab-Paclitaxel | 0 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of Gemcitabine | 49 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to D/C of Carboplatin | 15 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DR of Carboplatin | 21 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE leading to DI of Carboplatin | 50 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Death | 2 participants |
| Arm C: Gemcitabine + Carboplatin | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Treatment Related TEAE leading to death | 1 participants |
Secondary
Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)
The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
Time frame: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Population: The Safety/Treated population includes all randomized participants who received at least 1 dose of IP.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one DR for both IPs | 33.3 percentage of participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one dose missed for both IPs | 48.3 percentage of participants |
| Arm A: Nab-Paclitaxel + Gemcitabine | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one DI for both IPs | 38.3 percentage of participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one DR for both IPs | 46.9 percentage of participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one dose missed for both IPs | 45.3 percentage of participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one DI for both IPs | 70.3 percentage of participants |
| Arm C: Gemcitabine + Carboplatin | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one dose missed for both IPs | 56.3 percentage of participants |
| Arm C: Gemcitabine + Carboplatin | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one DI for both IPs | 73.4 percentage of participants |
| Arm C: Gemcitabine + Carboplatin | Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions) | ≥ one DR for both IPs | 51.6 percentage of participants |
Secondary
Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.
Time frame: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Population: The Safety/Treated population includes all randomized participants who received at least 1 dose of IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs | 21.7 percentage of participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs | 26.6 percentage of participants |
| Arm C: Gemcitabine + Carboplatin | Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs | 21.9 percentage of participants |
Secondary
Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy
The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.
Time frame: Cycle 6
Population: ITT includes all randomized participants regardless of whether they received any IP or had any efficacy assessments collected. Those who did not have disease progression or had not died as of the data cutoff date were censored at the time of the last radiologic assessment prior to the data cutoff date.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy | 55.7 percentage of participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy | 64.1 percentage of participants |
| Arm C: Gemcitabine + Carboplatin | Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy | 50.0 percentage of participants |
Secondary
Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.
Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.
Time frame: Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Population: ITT includes all randomized participants regardless of whether they received any IP or had any efficacy assessments collected. Those who did not have disease progression or had not died as of the data cutoff date were censored at the time of the last radiologic assessment prior to the data cutoff date.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment. | 39.3 percentage of participants |
| Arm B: Nab-Paclitaxel + Carboplatin | Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment. | 73.4 percentage of participants |
| Arm C: Gemcitabine + Carboplatin | Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment. | 43.9 percentage of participants |